



Innovating for
affordable healthcare

Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

12-6-214/A-1, Hyderabad Road,
RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91 - 8532 - 238876

CIN No. L85110KA1987PLC008739

E-Mail : info@vbsilpa.com Web: http://www.vbsilpa.com

Dated: 31st July, 2017

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

This is to inform you that the US FDA has completed inspection of Company's formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between 24th July and 28th July 2017. The inspection has now been closed by the US FDA with one minor observation. The Company is in the process of submission of corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**

Madhusudhan Reddy
Company Secretary & Compliance Officer

